Long-term zidovudine treatment of asymptomatic HIV-1-infected subjects
| Autor: | F. De Wolf, J. M. A. Lange, Peter Th. A. Schellekens, Jaap Goudsmit, A. P. Fiddian, R. A. Coutinho, J. W. Mulder, P. A. Cload, J. van der Noordaa |
|---|---|
| Přispěvatelé: | Other departments |
| Jazyk: | angličtina |
| Rok vydání: | 1990 |
| Předmět: |
Adult
CD4-Positive T-Lymphocytes Male medicine.medical_specialty Time Factors Anemia HIV Antigens medicine.medical_treatment HIV Core Protein p24 Gene Products gag Neutropenia Asymptomatic Gastroenterology Zidovudine Leukocyte Count Acquired immunodeficiency syndrome (AIDS) Virology Internal medicine Immunopathology medicine Humans Pharmacology Chemotherapy Acquired Immunodeficiency Syndrome business.industry Platelet Count Pneumonia Pneumocystis Viral Core Proteins Middle Aged medicine.disease Immunology HIV-1 Viral disease medicine.symptom business medicine.drug |
| Zdroj: | Antiviral research, 13(3), 127-138. Elsevier |
| ISSN: | 0166-3542 |
| DOI: | 10.1016/0166-3542(90)90028-6 |
| Popis: | Eighteen asymptomatic men with persistent human immunodeficiency virus type 1 (HIV-1) p24 antigenemia were treated with zidovudine 250-500 mg (+/- acyclovir 800 mg) 6-hourly for 4-12 weeks, and thereafter with zidovudine 500 mg (+/- acyclovir 1600 mg) 12-hourly for 92 weeks. Six additional HIV-1 p24 antigenemic subjects were treated with zidovudine 500 mg 12-hourly for 76 weeks. Disease progression occurred in 4 subjects, despite sustained reduction of serum HIV-1 p24 antigen levels: Pneumocystis carinii pneumonia was diagnosed after 60, 80, 90 and 93 weeks, respectively. The median CD4+ cell count of these 4 men at study entry was 0.2 x 10(9)/l, and it declined to 0.07 x 10(9)/l at the moment AIDS was diagnosed. In 20 subjects no disease progression occurred. The median CD4+ cell count of these 20 men at study entry was 0.4 x 10(9)/l and it was 0.45 x 10(9)/l at the end of the study period. Median serum HIV-1 p24 antigen levels at the end of the study period were 42% lower than at study entry in these 20 subjects. In 5/20 men, an initial decline was followed by a rise in antigen levels to above pretreatment value. Treatment with zidovudine was well tolerated. Anemia caused symptoms in 3/24 men, but prolonged leucopenia or neutropenia did not occur. None developed clinical or convincing biochemical evidence of zidovudine-associated myopathy. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|